New clinical trial collaboration for Cu-64 SAR-bisPSMA in prostate cancer
Sydney, Australia 24 March 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that an investigator-initiated trial (IIT) will commence shortly in the US investigating 64Cu SAR-bisPSMA in prostate cancer (NCT05286840)1. The X-Cancer’s investigator-led trial of SAR-bisPSMA…